PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35208952-0 2022 EGFR and COX-2 Dual Inhibitor: The Design, Synthesis, and Biological Evaluation of Novel Chalcones. Chalcones 89-98 epidermal growth factor receptor Homo sapiens 0-4 22200628-7 2012 However, DPhP also inhibited several other receptor tyrosine kinases including Tie-2, epithermal growth factor (EGF) receptor, EphB2, fibroblast growth factor (FGF) receptor 3 and insulin-like growth factor-1 (IGF-1) receptor, as revealed by a receptor tyrosine kinase array assay. Chalcones 9-13 epidermal growth factor receptor Homo sapiens 86-125 18387817-9 2008 Specifically, flavonoids and chalcones regulate expression of VEGF, matrix metalloproteinases (MMPs), EGFR and inhibit NFkappaB, PI3-K/Akt, ERK1/2 signalling pathways, thereby causing strong antiangiogenic effects. Chalcones 29-38 epidermal growth factor receptor Homo sapiens 102-106 30897725-6 2019 Only three chalcones (1c, 2a and 3e) had an inhibitory activity against EGFR-TK with a relative inhibition percentage that was close to the approved drug, erlotinib. Chalcones 11-20 epidermal growth factor receptor Homo sapiens 72-76 30897725-8 2019 From the above information, as well as ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, all three chalcones could serve as lead compounds for the development of EGFR-TK inhibitors. Chalcones 131-140 epidermal growth factor receptor Homo sapiens 194-198 29280968-6 2017 Furthermore, a molecular docking study was carried out to explain the observed effects and the binding modes of these chalcones with the EGFR TK and tubulin targets. Chalcones 118-127 epidermal growth factor receptor Homo sapiens 137-141